These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 26179339

  • 1. Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.
    White N, Flaherty I, Higgs P, Larance B, Nielsen S, Degenhardt L, Ali R, Lintzeris N.
    Drug Alcohol Rev; 2015 Nov; 34(6):623-9. PubMed ID: 26179339
    [Abstract] [Full Text] [Related]

  • 2. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L.
    Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M, Heikman P, Ojanperä I.
    Forensic Sci Int; 2013 Oct 10; 232(1-3):11-5. PubMed ID: 24053859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M, Mundin G, Sumner M.
    Eur J Pharm Sci; 2018 Sep 15; 122():125-133. PubMed ID: 29940217
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.
    Addiction; 2012 Jan 15; 107(1):142-51. PubMed ID: 21749526
    [Abstract] [Full Text] [Related]

  • 11. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.
    Med J Aust; 2009 Aug 03; 191(3):161-5. PubMed ID: 19645647
    [Abstract] [Full Text] [Related]

  • 12. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, Mattick R, Ali R, Horyniak D.
    Drug Alcohol Depend; 2011 Nov 01; 118(2-3):265-73. PubMed ID: 21565452
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overdose Risk and Client Characteristics Associated With the Injection of Buprenorphine at a Medically Supervised Injecting Center in Sydney, Australia.
    Power J, Salmon AM, Latimer J, Jauncey M, Day CA.
    Subst Use Misuse; 2019 Nov 01; 54(10):1646-1653. PubMed ID: 30973286
    [Abstract] [Full Text] [Related]

  • 15. Impact of a Mandated Change in Buprenorphine Formulation.
    Graddy R, Rastegar DA.
    J Addict Med; 2017 Nov 01; 11(6):435-439. PubMed ID: 28742624
    [Abstract] [Full Text] [Related]

  • 16. 'It's Fast, It's Quick, It Stops Me Being Sick': How to influence preparation of opioid tablets for injection.
    Lafferty L, Treloar C, van Breda N, Steele M, Hiley S, Flaherty I, Salmon A.
    Drug Alcohol Rev; 2017 Sep 01; 36(5):651-657. PubMed ID: 28493466
    [Abstract] [Full Text] [Related]

  • 17. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
    Hoffman K, Peyton ML, Sumner M.
    J Addict Med; 2017 Sep 01; 11(3):217-223. PubMed ID: 28353467
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film.
    White N, Ali R, Larance B, Zador D, Mattick RP, Degenhardt L.
    Drug Alcohol Rev; 2016 Jan 01; 35(1):76-82. PubMed ID: 26331899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.